<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1382">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05143164</url>
  </required_header>
  <id_info>
    <org_study_id>2021/2434</org_study_id>
    <nct_id>NCT05143164</nct_id>
  </id_info>
  <brief_title>Hydrocolloid Dressing for Catheter Exit Site Care in Peritoneal Dialysis Patients</brief_title>
  <official_title>Study of Hydrocolloid Dressing for Peritoneal Dialysis Catheter Exit Site Care in Peritoneal Dialysis Patients - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examine the use of hydrocolloid dressing for catheter exit-site care in&#xD;
      peritoneal dialysis patients. It is a pilot study, and participants will be randomized to&#xD;
      either receiving weekly hydrocolloid dressing or daily topical gentamicin cream for exit-site&#xD;
      care in peritoneal dialysis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal dialysis (PD) related infection is one of the main reasons for patients to&#xD;
      discontinue PD therapy. Routine exit-site care is crucial for the prevention of infections,&#xD;
      however, daily antibiotics use has been associated with the risk of developing drug-resistant&#xD;
      bacteria. Moreover, the burden of daily exit-site care can lead to non-compliance with&#xD;
      treatment. Hydrocolloid dressing has been used in the management of acute and chronic wounds&#xD;
      and is required to change once weekly, but its use has not been examined in the exit-site&#xD;
      wound in PD patients.&#xD;
&#xD;
      The study primarily aims to examine PD-related infection (exit site infection or peritonitis&#xD;
      rates) between patients using weekly hydrocolloid dressing (experimental group) and those&#xD;
      using daily topical application of gentamicin (control group) for exit-site care in PD&#xD;
      patients. Secondary aims include time to the first episode of PD-related infection, technique&#xD;
      failure, PD infection-related hospitalization, and adverse events. The study will also assess&#xD;
      the acceptability of dressing and quality of life between the two groups.&#xD;
&#xD;
      A total of 60 adult peritoneal dialysis patients will be recruited for the study. Patients&#xD;
      will be randomly assigned to either the experimental group or the control group. Participants&#xD;
      will be followed up at the 4th, 12th, and 24th week of study. The acceptability of the&#xD;
      dressing will be assessed using the treatment acceptability questionnaires. The quality of&#xD;
      life will be assessed using the ED 5D-5L questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal dialysis (PD)-related infection rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>PD-related infection (exit-site /tunnel infection or peritonitis) (episode per patient-year)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first episode of exit-site/tunnel infection or peritonitis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to first episode of exit-site/tunnel infection or peritonitis (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal dialysis infection-related hospitalization rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hospitalization due to peritoneal dialysis-related infection (episode per patient-year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technique failure rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Technique failure is defined as transfer to hemodialysis for &gt;= 30 days (episode per patient-year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events related to the dressing (local or systemic effects)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score using ED 5D 5L questionnaire</measure>
    <time_frame>at 12th week of study</time_frame>
    <description>Quality of life score using ED 5D 5L questionnaire (numerical scores)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment acceptability</measure>
    <time_frame>at 12th week of study</time_frame>
    <description>Acceptability of dressing will be measured by treatment acceptability questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peritoneal Dialysis Catheter Exit Site Infection</condition>
  <arm_group>
    <arm_group_label>Hydrocolloid dressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will use the weekly hydrocolloid dressing (Duoderm Extra Thin CGF dressing,10 x 10 cm) for peritoneal dialysis exit-site care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gentamicin cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will apply topical gentamicin cream to catheter exit site daily and cover with normal dressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hydrocolloid dressing</intervention_name>
    <description>Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.</description>
    <arm_group_label>Hydrocolloid dressing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin Sulfate, Topical</intervention_name>
    <description>Application of gentamicin to exit site daily</description>
    <arm_group_label>Gentamicin cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult peritoneal dialysis patients (â‰¥ 21 years old) and are followed up at&#xD;
             Singapore General Hospital (SGH)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to provide valid consent, patients who have known allergy to&#xD;
             hydrocolloid dressing, patients who have peritoneal dialysis catheter exit site&#xD;
             infection or peritonitis within the past 3 months, patients who have dialysate leak at&#xD;
             PD catheter exit site, pregnant women, patients with life-expectancy of &lt; 1 year or&#xD;
             patients who are currently involved in another study for peritoneal dialysis catheter&#xD;
             exit site care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Htay Htay</last_name>
    <phone>63214436</phone>
    <email>htay.htay@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peritoneal dialysis</keyword>
  <keyword>exit-site care</keyword>
  <keyword>exit-site dressing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

